Harmony Biosciences Holdings, Inc. (HRMY) has reported its preliminary net product revenue figures for both the fourth quarter and the full fiscal year 2024.
For the quarter concluding on December 31, the biotechnology firm anticipates net product revenue to reach approximately $201 million, marking an increase from $168.4 million in the corresponding period of 2023.
For the entirety of fiscal year 2024, anticipated net product revenue is projected at approximately $714 million, up from $582 million in the previous year.
Analysts had predicted revenues averaging $198.6 million for the fourth quarter and $712.05 million for the fiscal year 2024.
Looking forward, Harmony projects net revenue to range between $820 million and $860 million for fiscal year 2025.
Currently, Harmony's share price is experiencing a rise of 9.18 percent, reaching $36.97 on the Nasdaq.
